This article by Dr. Andrea Nicolini et al. is published in Current Medicinal Chemistry, Volume 25, 2018
Breast cancer, in the stage with distant metastases, is an incurable disease with a 5 years survival rate of about 5-10% (1). Immunotherapy has recently improved survival in metastatic breast cancer patients with breast cancer harbouring the expression of HER 2 receptor. Particularly in HER 2 positive patients pertuzumab plus trastuzumab and docetaxel is the recommended first line regimen and in triple negative breast cancer patients (TNBC) bevacizumab plus paclitaxel or docetaxel is a reasonable option. In the metastatic breast cancer patients responding to conventional antiestrogens without or with HER 2 receptor, the addition of interferon beta-interleukin 2 sequence importantly prolongs quality and length of survival in a pilot study of 42 patients. In fact, in all patients median progression-free survival (PFS) from the beginning of hormone-therapy was 33 months, (Fig.1) and median OS 82 months (Fig 2); cumulative survival at 5 and 10 years±SE were 0.69±0.07 and 0.15±0.06 respectively. In the overall population these data confirm the previously reported findings (2-4). In the luminal sub-type, median PFS was 33 months (Fig.3) and median OS was 91 months (Fig 4).
In the non-luminal sub-type, median PFS was 32 months and median OS was 59 months. Therefore, a relevant PFS and OS improvement occurred both in luminal and in non-luminal molecular subtypes compared with that expected in similar populations. In fact, equal or less than 10 months [5, 6] is the reported median PFS in non-luminal breast cancer patients and it ranges from 11.2 months [7] to 15.6 months [8] in luminal patients. Moreover, 30.6 and 24.4 months have been reported as the best median OS in luminal and non-luminal breast cancer patients respectively [9]. In some observational or phase I/II studies on HER 2 peptide/protein vaccines promising although preliminary findings have been reported.
For more information, please visit: http://www.eurekaselect.com/159672
[1] | Cheng, Y.C.; Ueno, N.T. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer, 2012, 19(3), 191-199. [http://dx.doi.org/10.1007/s12282-011-0276-3] [PMID: 21567170] |
[2] | Nicolini, A.; Carpi, A.; Ferrari, P.; Biava, P.M.; Rossi, G. Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update. Curr. Drug Targets, 2016, 17(10), 1127-1139. [http://dx.doi.org/10.2174/1389450117666160201114752] [PMID: 26844558] |
[3] | Nicolini, A.; Carpi, A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother., 2005, 59(5), 253-263. [http://dx.doi.org/10.1016/j.biopha.2004.05.019] [PMID: 15913946] |
[4] | Nicolini, A.; Rossi, G.; Ferrari, P.; Carpi, A. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer. Biomed. Pharmacother., 2014, 68(2), 171-178. [http://dx.doi.org/10.1016/j.biopha.2013.11.005] [PMID: 24491318] |
[5] | Zhang, J.; Fan, M.; Xie, J.; Wang, Z.; Wang, B.; Zhang, S.; Wang, L.; Cao, J.; Tao, Z.; Li, T.; Hu, X. Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. Oncotarget, 2015, 6(40), 43135-43143. [http://dx.doi.org/10.18632/oncotarget.5654] [PMID: 26447756] |
[6] | Fan, Y.; Xu, B.H.; Yuan, P.; Ma, F.; Wang, J.Y.; Ding, X.Y.; Zhang, P.; Li, Q.; Cai, R.G. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann. Oncol., 2013, 24(5), 1219-1225. [http://dx.doi.org/10.1093/annonc/mds603] [PMID: 23223332] |
[7] | Lam, S.W.; de Groot, S.M.; Honkoop, A.H.; Jager, A.; ten Tije, A.J.; Bos, M.M.; Linn, S.C.; van den Bosch, J.; Kroep, J.R.; Braun, J.J.; van Tinteren, H.; Boven, E. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. Eur. J. Cancer, 2014, 50(18), 3077-3088. [http://dx.doi.org/10.1016/j.ejca.2014.10.008] [PMID: 25459393] |
[8] | Dickler, M.N.; Barry, W.T.; Cirrincione, C.T.; Ellis, M.J.; Moynahan, M.E.; Innocenti, F.; Hurria, A.; Rugo, H.S.; Lake, D.E.; Hahn, O.; Schneider, B.P.; Tripathy, D.; Carey, L.A.; Winer, E.P.; Hudis, C.A. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J. Clin. Oncol., 2016, 34(22), 2602-2609. [http://dx.doi.org/10.1200/JCO.2015.66.1595] [PMID: 27138575] |
[9] | Zielinski, C.; Láng, I.; Inbar, M.; Kahán, Z.; Greil, R.; Beslija, S.; Stemmer, S.M.; Zvirbule, Z.; Steger, G.G.; Melichar, B.; Pienkowski, T.; Sirbu, D.; Petruzelka, L.; Eniu, A.; Nisenbaum, B.; Dank, M.; Anghel, R.; Messinger, D.; Brodowicz, T. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol., 2016, 17(9), 1230-1239. [http://dx.doi.org/10.1016/S1470-2045(16)30154-1] [PMID: 27501767] |